AstraZeneca signs deal on cancer drugs with Immunocore
LONDON (Reuters) - AstraZeneca has signed a deal with private British biotech company Immunocore to boost its experimental cancer drug pipeline as it seeks to find new medicines to replace those going off patent.
Immunocore is developing drugs known as "ImmTACs" that exploit the power of the body's own immune system to find and kill diseased cells.
AstraZeneca said on Wednesday its MedImmune unit would pay Immunocore $20 million upfront per program and the biotech firm would then be eligible to get up to $300 million in development and commercial milestone payments for each target program, plus royalties on any eventual sales.
(Reporting by Ben Hirschler)
SYDNEY - Asian markets were finding their feet on Tuesday after a rocky ride the previous session, though uncertainty about the true state of China's economy kept nerves frayed and commodity prices restrained.
- U.S. small businesses borrowed more money in January than they did a year earlier, signaling continued growth in the economy despite a spate of cold weather that has been blamed for weakness in many other indicators of activity.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.